MT. KISCO, N.Y., Sept. 16, 2015 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) - announced today that Sven Rohmann M.D., PhD, M.B.A. has joined its Board of Directors.
Previously, Dr. Rohmann spent 10 years at Merck Serono and has an excellent track record across scientific, clinical, and commercial markets. During his tenure at Merck, he was instrumental in the successful licensing of Erbitux from ImClone, which has grown to over $1 billion in annual revenues. Sven also played an integral role in the establishment of Merck Oncology. Dr. Rohmann stated “In the coming days, we at Immudyne anticipate that we will be able to disclose publicly, the first new market opportunity for our proprietary oral and topical delivery technology. We see immediate opportunities. I am very excited where we are taking the Company.”
Mr. McLaughlin commented, “Immudyne has always been a research driven Company. Sven plays a key role by serving as Immudyne’s Chief Medical Officer, as well as bringing unique insights into the practical market applications for the Immudyne core scientific discoveries. Dr. Rohmann is the major driver in our first new market application for Immudyne's delivery technology. As Sven mentioned, we expect to disclose more about this opportunity very soon.”
Immundyne, its management team, Mr. McLaughlin, Dr. Rohmann, Chairman Anthony Bruzzese, M.D., and directors Joseph DiTrolio, M.D., John Strawn, Esq., as well as significant shareholder, Dr. Lane Deyoe, have purchased additional shares of the company’s common stock in open market transactions, as reflected in the Company’s 10K, and may do so in the future.
ImmuDyne has developed proprietary topical and oral delivery technologies, with several new market opportunities.
The Company also manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. ImmuDyne’s intellectual property is protected by patents and/or trade secrets.
Immudyne has offices located in Mt. Kisco, NY, Tampa, FL, and Florence, KY.
Additional information can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
CONTACT: Immudyne, Inc. Mark McLaughlin +1-914-714-8901 MarkMcL@immudyne.com